相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Madeleine M. Hipp et al.
BLOOD (2008)
Targeting V600EB-Raf and AW using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development
Melissa A. Tran et al.
CANCER RESEARCH (2008)
Akt and mutant V600EB-Raf cooperate to promote early melanoma development
Mitchefl Cheung et al.
CANCER RESEARCH (2008)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2008)
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel
Nikolas K. Haass et al.
CLINICAL CANCER RESEARCH (2008)
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines
Rebecca Leboeuf et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 study group
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Major response to imatinib mesylate in KIT-mutated melanoma
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
Konstantinos G. Lasithiotakis et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma
Roland Houben et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
MTOR is activated in the majority of malignant melanomas
Magdalena Karbowniczek et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment
F. Meier et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
Chris Folkins et al.
CANCER RESEARCH (2007)
GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells
Lise O. Andrieux et al.
CANCER RESEARCH (2007)
Melanoma biology and new targeted therapy
Vanessa Gray-Schopfer et al.
NATURE (2007)
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species
Monique Verhaegen et al.
CANCER RESEARCH (2006)
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
Alastair J. King et al.
CANCER RESEARCH (2006)
Stress and mTORture signaling
J. H. Reiling et al.
ONCOGENE (2006)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen et al.
BRITISH JOURNAL OF CANCER (2006)
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
KSM Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation
B Bedogni et al.
CANCER CELL (2005)
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
KR Molhoek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
CCI-779 in metastatic melanoma - A phase II trial of the California Cancer Consortium
K Margolin et al.
CANCER (2005)
A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040
YL Wang et al.
NEOPLASIA (2005)
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants
HM McDaid et al.
CANCER RESEARCH (2005)
Mutant V599EB-RAF regulates growth and vascular development of malignant melanoma tumors
A Sharma et al.
CANCER RESEARCH (2005)
Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/akt and raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodericient mice
B Bedogni et al.
CANCER RESEARCH (2004)
Deregulated Akt3 activity promotes development of malignant melanoma
JM Stahl et al.
CANCER RESEARCH (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
分享论文
